⌘K
Loading ticker…
As of 2026-08-24, Nurix Therapeutics, Inc. Common stock (NRIX) has a 3-month relative strength percentile of 94 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 75. The current market Stance is 47.8 (Neutral). Sector: Healthcare, ranked 3 of 11. Average daily range 3.9%, relative volume 0.78×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
NRIX is in a stage 2 uptrend, week 8. Extended from base. VCP detected: inconclusive. Distance from 50d / 200d: 11.9% / 43.6%.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
Diluted EPS, last 8 quarters. Loss makers are judged by progress toward breakeven.
NRIX is held by 21 ETFs as of May 2026. Top owner: VTWO at 0.05% weight, $9M notional. Top 3 carry $22M.
Held by 54 ETFs · $261M across latest filings · largest weight 2.33% (ARKG).
Top 10 by value, from SEC N-PORT-P filings dated May 2026.
| ETF | Weight | Value | Δ |
|---|---|---|---|
| VTWO | 0.05% | $9M | — |
| SCHASchwab U.S. Small-Cap ETF | 0.04% | $8M | — |
| VHTVanguard Health Care ETF | 0.02% | $4M | — |
| VTWV | 0.11% | $1M | — |
| ESML | 0.05% | $1M | — |
Strong relative strength, but attention is quiet relative to this name’s own recent norm. Academic work links low public attention to better forward returns on average — context to weigh, not a forecast.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
Daily range, ATR, beta, and the math for a 1-ADR stop.
YoY sales growth, last 8 quarters. Sales must back the earnings story.
TTM operating margin. Expansion = real operating leverage.
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
| 0.00% |
| $984K |
| — |
| ONEQ | 0.01% | $684K | — |
| HEAL | 1.62% | $406K | +0.45 pp |
| AVSC | 0.01% | $250K | −0.04 pp |
| GSSC | 0.02% | $198K | −0.02 pp |
Showing 10 of 21 ETF owners.
As filed in N-PORT — quarterly holdings with up to ~60-day publication lag. Not live positioning.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NRIX Jan avg: -4.95% median: -4.15% win: 50% σ: 16.15% n: 4 2022-04-12 → 2026-07-31 | NRIX Feb avg: 2.03% median: -12.47% win: 25% σ: 37.31% n: 4 2022-04-12 → 2026-07-31 | NRIX Mar avg: -3.21% median: -4.39% win: 25% σ: 17.29% n: 4 2022-04-12 → 2026-07-31 | NRIX Apr avg: -3.10% median: -2.95% win: 40% σ: 11.56% n: 5 2022-04-12 → 2026-07-31 | NRIX May avg: 5.16% median: 5.09% win: 60% σ: 16.09% n: 5 2022-04-12 → 2026-07-31 | NRIX Jun avg: 20.11% median: 25.57% win: 80% σ: 16.44% n: 5 2022-04-12 → 2026-07-31 | NRIX Jul avg: 4.51% median: -1.14% win: 40% σ: 12.49% n: 5 2022-04-12 → 2026-07-31 | NRIX Aug avg: -3.94% median: -6.95% win: 25% σ: 14.33% n: 4 2022-04-12 → 2026-07-31 (current) | NRIX Sep avg: -9.15% median: -9.18% win: 0% σ: 6.71% n: 4 2022-04-12 → 2026-07-31 | NRIX Oct avg: 4.56% median: 3.54% win: 50% σ: 28.56% n: 4 2022-04-12 → 2026-07-31 | NRIX Nov avg: 8.79% median: 4.30% win: 50% σ: 20.55% n: 4 2022-04-12 → 2026-07-31 | NRIX Dec avg: 11.76% median: -2.04% win: 50% σ: 37.39% n: 4 2022-04-12 → 2026-07-31 |